These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 26266196)

  • 41. What combinations of agomelatine with other antidepressants could be successful during the treatment of major depressive disorder or anxiety disorders in clinical practice?
    Potměšil P
    Ther Adv Psychopharmacol; 2019; 9():2045125319855206. PubMed ID: 31312426
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The efficacy and safety of agomelatine, sertraline, and escitalopram for senile post-stroke depression: A randomized double-blind placebo-controlled trial.
    Yao XW; Li YL; Yu ZJ; Mo CY; Pan HS; Li CY
    Clin Neurol Neurosurg; 2021 Apr; 205():106651. PubMed ID: 33940563
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The Daily Functionality in a Major Depressive Episode Cohort of Romanian Patients - a Non-Interventional Study.
    Prelipceanu D; Purnichi T; Marinescu V; Matei V
    Maedica (Bucur); 2015 Mar; 10(1):39-43. PubMed ID: 26225148
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Agomelatine in the treatment of depressive disorders in clinical practice: multicenter observational CHRONOS study.
    Ivanov SV; Samushiya MA
    Neuropsychiatr Dis Treat; 2014; 10():631-9. PubMed ID: 24790445
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Agomelatine versus fluoxetine in glycemic control and treating depressive and anxiety symptoms in type 2 diabetes mellitus subjects: a single-blind randomized controlled trial.
    Che T; Teng X; Huang Q; Mu Y; Tang X; Mu X; Wei Y
    Neuropsychiatr Dis Treat; 2018; 14():1527-1533. PubMed ID: 29942131
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Agomelatine in unipolar depression in clinical practice: a retrospective chart review.
    Langan J; Shajahan P; Martin D; Carleton R
    Ther Adv Psychopharmacol; 2011 Dec; 1(6):175-80. PubMed ID: 23983944
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Comparative safety and efficacy of tibolone and escitalopram in postmenopausal women.
    Raj R; Sharma N; Garg R; Goyal E
    Ind Psychiatry J; 2021 Oct; 30(Suppl 1):S140-S148. PubMed ID: 34908680
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Agomelatine versus paroxetine in treating depressive and anxiety symptoms in patients with chronic kidney disease.
    Chen JW; Xie SQ
    Neuropsychiatr Dis Treat; 2018; 14():547-552. PubMed ID: 29497298
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Agomelatine in the treatment of mild-to-moderate depression in patients with cardiovascular disease: results of the national multicenter observational study PULSE.
    Medvedev VE
    Neuropsychiatr Dis Treat; 2017; 13():1141-1151. PubMed ID: 28461750
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The treatment of depressed chinese americans using qigong in a health care setting: a pilot study.
    Yeung A; Slipp LE; Jacquart J; Fava M; Denninger JW; Benson H; Fricchione GL
    Evid Based Complement Alternat Med; 2013; 2013():168784. PubMed ID: 23690836
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Effects of escitalopram with a Chinese traditional compound Jiuweizhenxin-keli on mismatch negativity and P50 in patients with major depressive disorders.
    Kuang W; Tian L; Yue L; Li J
    Neuropsychiatr Dis Treat; 2016; 12():1935-41. PubMed ID: 27536116
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Agomelatine and its therapeutic potential in the depressed patient.
    Kennedy SH; Eisfeld BS
    Neuropsychiatr Dis Treat; 2007 Aug; 3(4):423-8. PubMed ID: 19300571
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Major Depressive Disorder and Difference between Genders.
    Sabic D; Sabic A; Bacic-Becirovic A
    Mater Sociomed; 2021 Jun; 33(2):105-108. PubMed ID: 34483737
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Development and Internal Validation of a Novel Model to Identify Inflammatory Biomarkers of a Response to Escitalopram in Patients With Major Depressive Disorder.
    Zhou J; Zhou J; Sun Z; Feng L; Zhu X; Yang J; Wang G
    Front Psychiatry; 2021; 12():593710. PubMed ID: 34093252
    [No Abstract]   [Full Text] [Related]  

  • 55. The ability of early changes in motivation to predict later antidepressant treatment response.
    Gorwood P; Vaiva G; Corruble E; Llorca PM; Baylé FJ; Courtet P
    Neuropsychiatr Dis Treat; 2015; 11():2875-82. PubMed ID: 26635476
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Randomized controlled comparison of agomelatine and escitalopram: Concerns about study design and methods.
    Pal S; Pinto EF; Raut NB; Banwari G; Andrade C
    J Pharmacol Pharmacother; 2016; 7(3):152. PubMed ID: 27651715
    [No Abstract]   [Full Text] [Related]  

  • 57. Early effect on general interest, and short-term antidepressant efficacy and safety of agomelatine (25-50mg/day) and escitalopram (10-20mg/day) in outpatients with Major Depressive Disorder. A 12-week randomised double-blind comparative study.
    Udristoiu T; Dehelean P; Nuss P; Raba V; Picarel-Blanchot F; de Bodinat C
    J Affect Disord; 2016 Jul; 199():6-12. PubMed ID: 27054610
    [TBL] [Abstract][Full Text] [Related]  

  • 58. A comparative study of the clinical efficacy and safety of agomelatine with escitalopram in major depressive disorder patients: A randomized, parallel-group, phase IV study.
    Urade CS; Mahakalkar SM; Tiple PG
    J Pharmacol Pharmacother; 2015; 6(4):198-203. PubMed ID: 26813706
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Vortioxetine: a new antidepressant to treat depressive episodes].
    Colle R; Corruble E
    Encephale; 2016 Feb; 42(1):48-58. PubMed ID: 26358483
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Better sexual acceptability of agomelatine (25 and 50 mg) compared to escitalopram (20 mg) in healthy volunteers. A 9-week, placebo-controlled study using the PRSexDQ scale.
    Montejo AL; Deakin JF; Gaillard R; Harmer C; Meyniel F; Jabourian A; Gabriel C; Gruget C; Klinge C; MacFayden C; Milligan H; Mullings E; Goodwin G
    J Psychopharmacol; 2015 Oct; 29(10):1119-28. PubMed ID: 26268533
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.